European Trial Into Mpox Infection

PHASE4RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 9, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions
Monkeypox
Interventions
DRUG

Tecovirimat Oral Capsule

600 mg, twice daily, 14 days.

DRUG

Placebo

3 capsules, twice daily, 14 days.

Trial Locations (12)

1200

NOT_YET_RECRUITING

Cliniques Universitaires St. Luc, Brussels

2000

RECRUITING

Institute of Tropical Medicine, Antwerp

28040

NOT_YET_RECRUITING

Hospital Clinico San Carlos, Madrid

28046

NOT_YET_RECRUITING

Hospital Universitario La Paz, Madrid

41009

NOT_YET_RECRUITING

Hospital Universitario Virgen Macarena, Seville

53127

NOT_YET_RECRUITING

Universitätsklinikum Bonn, Bonn

75010

NOT_YET_RECRUITING

APHP St. Louis, Paris

Unknown

NOT_YET_RECRUITING

Hospital Luigi Sacco, Milan

NOT_YET_RECRUITING

Azienda Ospedaliera Universitaria Integrata Verona - AOUI Verona, Verona

NOT_YET_RECRUITING

Amsterdam UMC - AMC, Amsterdam

0450

NOT_YET_RECRUITING

Oslo Unversity Hospital, Oslo

1169-050

NOT_YET_RECRUITING

Hospital de Santo António dos Capuchos, Lisbon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

European Clinical Research Alliance for Infectious Diseases (ECRAID)

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Hospital Universitario La Paz

OTHER

collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

collaborator

Universiteit Antwerpen

OTHER

lead

Miquel Ekkelenkamp

OTHER

NCT06156566 - European Trial Into Mpox Infection | Biotech Hunter | Biotech Hunter